Pfizer inks an early-stage collaboration deal as it invests in another startup; Stem cell startup lands cardiac tech

A busy Pfizer is partnering with South San Francisco-based Ab Initio Biotherapeutics on the discovery of new GPCR activator drugs. Pfizer is investing in the company as part of this collaboration and handing over a deal that includes an unspecified upfront as well as milestones. Just a couple of days ago Pfizer helped launch a new oncolytic virus biotech in Alameda, CA dubbed Ignite. The pharma giant took a 50% stake in that upstart.

BlueRock, a $225 million stem cell startup from Bayer and Versant Ventures, has grabbed licensing rights to technology from VistaGen on producing cardiac stem cells for treating heart disease. VistaGen gains $1.25 million up front.

Waltham, MA-based Syndax has expanded its CRADA relationship with the NCI to include studies of a combination of entinostat and SNDX-6352 for neoplastic diseases.

The UK’s Pulmagen Therapeutics says its Japanese partners at Teijin gathered positive Phase II data on their CRTh2 antagonist in eosinophilic asthma patients. Pulmagen is looking for another partner to help advance the program.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->